![]() |
市場調査レポート
商品コード
1563123
眼用アレルギー治療薬の世界市場:タイプ・薬剤クラス・治療形態・流通チャネル・地域別の予測 (~2032年)Global Eye Allergy Treatment Market Research Report Information By Type, By Drug Class, By Treatment Form, By Distribution Channel And By Region Forecast to 2032 |
||||||
|
眼用アレルギー治療薬の世界市場:タイプ・薬剤クラス・治療形態・流通チャネル・地域別の予測 (~2032年) |
出版日: 2024年08月10日
発行: Market Research Future
ページ情報: 英文 147 Pages
納期: 即納可能
![]() |
眼用アレルギー治療薬の市場規模は、2023年の33億5,000万米ドル、2024年の35億5,000万米ドルから、予測期間中は6.23%のCAGRで推移し、2032年には56億2,000万米ドルの規模に成長すると予測されています。眼アレルギーの有病率の上昇、老齢人口の拡大、高い需要を満たす医薬品上市の増加などが市場成長の原動力となっています。
世界で眼アレルギーが増加していることが同市場の拡大を後押ししています。例えば、Alconは2020年2月、約6,600万人の米国人が眼アレルギーを持っていると推計しています。さらに、高齢者人口の増加も市場を牽引しています。Senior Home Plusによると、高齢者の眼アレルギーは、免疫システムの低下、慢性的な健康問題、涙の分泌量の減少、いくつかの薬剤の副作用などによって引き起こされます。
地域別インサイト
北米は2023年に最大の市場シェアを示しました。市場規模は予測期間中に4.29%のCAGRで推移し、2032年には19億4,000万米ドルの規模に達すると予測されています。一方、アジア太平洋地域は予測期間中に最大のCAGR 7.11%で成長すると予測されています。
欧州は第2位の市場シェアを占めています。その理由は、眼科疾患患者の増加、高度な治療施設のアベイラビリティ、医療費の増加、高度な治療法の導入、強力な医療インフラの存在などです。また、政府の取り組みが活発化していることも市場の拡大に拍車をかけています。さらに、高齢者人口の増加も同市場を牽引しています。
アジア太平洋地域は急成長地域です。患者人口の多さ、迅速な技術の進歩、市場の発展の見込みなどが同地域の市場成長に寄与しています。さらに、老人人口の増加も市場を牽引しています。
当レポートでは、世界の眼用アレルギー治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
Global Eye Allergy Treatment Market Research Report Information By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) And By Region Forecast to 2032
In 2023, the market for eye allergy treatments was estimated to be worth USD 3.35 billion. The market is expected to expand from USD 3.55 billion in 2024 to USD 5.62 billion by 2032, representing a compound annual growth rate (CAGR) of 6.23% over the forecast period (2024-2032). The rising prevalence of ocular allergies, an expanding geriatric population, and increased medicine launches to fulfill high demand are driving market expansion.
The growing frequency of eye allergies around the world is driving the expansion of the Eye Allergy Treatment Market. For example, in February 2020, Alcon, a Novartis AG (US) firm, estimated that approximately 66 million Americans have ocular allergies. Furthermore, the growing senior population is driving the eye allergy treatment market. According to Senior Home Plus (UK), eye allergies in the older population are caused by a compromised immune system, chronic health issues, decreased tear production, and some drug adverse effects. The market is poised for tremendous development. For example, according to the World Population Prospects 2022, the population above the age of 65 is expanding faster than the population below that age. Furthermore, it has been anticipated that the share of the global population aged 65 and up will increase from 10% in 2022 to 16% by 2050. Furthermore, the growing senior population in Asia-Pacific will provide profitable growth prospects in the coming years. According to the Asia-Pacific Report on Population Ageing 2022, Asia-Pacific had roughly 670 million persons aged 60 and up in 2022. Thus, the increasing prevalence of eye allergies, as well as the growing senior population, are driving global market expansion.
Market Segment insights
The Eye Allergy Treatment Market is divided into five types: seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis.
The Eye Allergy Treatment Market is divided into pharmacological classes, including antihistamines, mast cell stabilizers, NSAIDS, corticosteroids, decongestants, immunotherapy allergy shots, and others.
The Eye Allergy Treatment Market is divided into three segments based on treatment form: eyedrops, injectables, and tablets/capsules.
The Eye Allergy Treatment Market is divided into three distribution channels: hospital pharmacies, internet pharmacies, and retail pharmacies.
Regional insights
The Eye Allergy Treatment Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America had the biggest market share in 2023 and is expected to reach USD 1.94 billion by 2032, representing a CAGR of 4.29% over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.11% over the projection period.
The Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share due to an increasing patient population with eye disorders, the availability of advanced treatment facilities, rising healthcare expenditure, the introduction of advanced therapies into the market, and the presence of a strong healthcare infrastructure. In addition, increased government initiatives are fueling market expansion. Furthermore, the growing senior population is driving the eye allergy treatment market.
Asia-Pacific is the fastest-growing region for Eye Allergy Treatment Market. The presence of a large patient population, quick technological advancement, and numerous prospects for market development all contribute to the growth of the Asia-Pacific eye allergy treatment market. Furthermore, the growing geriatric population is driving the market for eye allergy treatments in this region.
Major participants in the Eye Allergy Treatment Market include Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Alcon, and Bayer AG.